Celularity Statistics
Total Valuation
Celularity has a market cap or net worth of $44.31 million. The enterprise value is $112.40 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Celularity has 23.95 million shares outstanding. The number of shares has increased by 22.89% in one year.
| Current Share Class | 23.95M |
| Shares Outstanding | 23.95M |
| Shares Change (YoY) | +22.89% |
| Shares Change (QoQ) | +1.44% |
| Owned by Insiders (%) | 13.53% |
| Owned by Institutions (%) | 14.67% |
| Float | 11.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.72 |
| Forward PS | n/a |
| PB Ratio | 4.57 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.38, with a Debt / Equity ratio of 7.79.
| Current Ratio | 0.38 |
| Quick Ratio | 0.27 |
| Debt / Equity | 7.79 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.15 |
Financial Efficiency
Return on equity (ROE) is -232.51% and return on invested capital (ROIC) is -26.18%.
| Return on Equity (ROE) | -232.51% |
| Return on Assets (ROA) | -17.42% |
| Return on Invested Capital (ROIC) | -26.18% |
| Return on Capital Employed (ROCE) | -48.80% |
| Revenue Per Employee | $440,813 |
| Profits Per Employee | -$470,667 |
| Employee Count | 123 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 2.69 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.71% in the last 52 weeks. The beta is 0.76, so Celularity's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -37.71% |
| 50-Day Moving Average | 1.87 |
| 200-Day Moving Average | 2.10 |
| Relative Strength Index (RSI) | 47.26 |
| Average Volume (20 Days) | 73,066 |
Short Selling Information
The latest short interest is 1.44 million, so 6.00% of the outstanding shares have been sold short.
| Short Interest | 1.44M |
| Short Previous Month | 1.48M |
| Short % of Shares Out | 6.00% |
| Short % of Float | 12.29% |
| Short Ratio (days to cover) | 13.86 |
Income Statement
In the last 12 months, Celularity had revenue of $54.22 million and -$57.89 million in losses. Loss per share was -$2.64.
| Revenue | 54.22M |
| Gross Profit | 39.23M |
| Operating Income | -38.55M |
| Pretax Income | -196.29M |
| Net Income | -57.89M |
| EBITDA | -30.63M |
| EBIT | -38.55M |
| Loss Per Share | -$2.64 |
Full Income StatementBalance Sheet
The company has $738,000 in cash and $68.84 million in debt, giving a net cash position of -$68.10 million or -$2.84 per share.
| Cash & Cash Equivalents | 738,000 |
| Total Debt | 68.84M |
| Net Cash | -68.10M |
| Net Cash Per Share | -$2.84 |
| Equity (Book Value) | 8.84M |
| Book Value Per Share | 0.39 |
| Working Capital | -33.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.40 million and capital expenditures -$161,000, giving a free cash flow of -$6.56 million.
| Operating Cash Flow | -6.40M |
| Capital Expenditures | -161,000 |
| Free Cash Flow | -6.56M |
| FCF Per Share | -$0.27 |
Full Cash Flow StatementMargins
Gross margin is 72.36%, with operating and profit margins of -71.10% and -106.77%.
| Gross Margin | 72.36% |
| Operating Margin | -71.10% |
| Pretax Margin | -106.77% |
| Profit Margin | -106.77% |
| EBITDA Margin | -56.49% |
| EBIT Margin | -71.10% |
| FCF Margin | n/a |
Dividends & Yields
Celularity does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.89% |
| Shareholder Yield | -22.89% |
| Earnings Yield | -130.66% |
| FCF Yield | -14.81% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 29, 2024. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Feb 29, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
Celularity has an Altman Z-Score of -10 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10 |
| Piotroski F-Score | 4 |
